An open-label extension study of CACZ885H2356E1 on the treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/ or colchicine are contraindicated, not tolerated or ineffective - H2356E2

Conditions: Treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/ or colchicine are contraindicated, not tolerated or ineffective
MedDRA version: 13.1Level: PTClassification code 10018627Term: GoutSystem Organ Class: 10027433 - Metabolism and nutrition disorders

Registration Number: EUCTR2010-019559-23-EE

Lead Sponsor: ovartis Pharma Services AG

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: ot Recruiting

Sex: All

Target Recruitment: 200

Inclusion Criteria

Patients eligible for inclusion in this study have to fulfill all of the following criteria:
1.Signed written informed consent before any study procedure is performed.
2.Patients who have either:
•Completed the first extension study CACZ885H2356E1 (a patient is defined as completing the first extension study if they completed the study up to and including Visit 10) or
•Experienced a ninth new flare requiring treatment with study drug within the core study CACZ885H2356 and the first extension study CACZ885H2356E1

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Patients fulfilling any of the following criteria are not eligible for inclusion in this study:
1.Continuation in this extension study is considered inappropriate by the treating physician.
2.Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception, confirmed by a positive pregnancy test (serum or urine), and until the termination of gestation.
3.Female patients being physiologically capable of becoming pregnant UNLESS they are:
•Female patients whose career, lifestyle, or sexual orientation precludes intercourse with a male partner
•Female patients whose partners have been sterilized by vasectomy or other means
•Using an acceptable method of contraception with a failure rate (Pearl Index (PI)) < 1, reliable contraception should be maintained throughout the study and for 2 months after last study drug administration.